- cafead May 07, 2024 at 11:22: AM
via Illumina (NASDAQ:ILMN) has decided to proceed with a spin-off option for its $7.1B acquisition, Grail, after EU officials ordered the U.S. genomics company to divest the cancer test developer it acquired in 2021 despite antitrust concerns.
article source
article source